New Trends in Nucleoside Biotechnology by Mikhailopulo, I.A. & Miroshnikov, A.I.
36 | ACTA NATURAE |  VOL. 2  № 2 (5)  2010
REVIEWS
New Trends in Nucleoside Biotechnology
I.A. Mikhailopulo1*, A.I. Miroshnikov2
1Institute of Bioorganic Chemistry, National Academy of Sciences, Belarus 
2Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
*E-mail: igor_mikhailo@yahoo.de 
Received 29.04.2010
Copyright © 2010 Park-media, Ltd. This is an open access article distributed under the Creative 
Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
ABSTRACT This review focuses on new trends in nucleoside biotechnology, which have emerged during the last decade. 
Continuously growing interest in the study of this class of compounds is fueled by a number of factors: (i) a growing 
need for large-scale  production of natural 2′-deoxy-β-D-ribonucleosides as well as their analogs with modifications in 
the carbohydrate and base fragments, which can then be used for the synthesis and study of oligonucleotides, includ-
ing short-interfering RNA (siRNA), microRNA (miRNA), etc.; (ii) a necessity for the development of efficient practi-
cal technologies for the production of biologically important analogs of natural nucleosides, including a number of 
anticancer and antiviral drugs; (iii) a need for further study of known and novel enzymatic transformations and their 
use as tools for the efficient synthesis of new nucloside analogs and derivates with biomedical potential. This article 
will review all of these aspects and also include a brief retrospect of this field of research. 
KEYWORDS nucleosides, nucleic acid metabolism enzymes, chemoenzymaticsynthesis, bio-mimetic synthesis.
INTRODUCTION
Nucleosides are a large family of natural compounds and their 
chemically modified analogs, which are characterized by great 
structural diversity. The four 2′-deoxy-β-D-ribonucleosides 
of adenine (1) and guanine (2), and thymine (3) and cytosine 
(4), along with the related four β-D-ribonucleosides (5-8), 
are the main constituents of DNA and RNA, respectively 
(Scheme 1). Analogs of these natural nucleosides with vari-
ously modified carbohydrate and/or aglycon fragments have 
been found in RNA’s and are also included into a sub-family 
of nucleoside antibiotics which is also characterized by great 
structural diversity. 5’-Phosphorylated nucleosides, called 
nucleotides, are important metabolites of DNA and RNA bio-
synthesis, and they also act as co-substrates and cofactors of 
a large number of biochemical transformations. 
The first identified natural representative of this family, 
inosine-5’-monophosphate (9; IMP; the name inosine origi-
nates from the Greek word inos – muscle), was isolated from 
beef extract by J.F. von Liebig in 1847. He also described its 
taste intensifier property; synthesis of IMP from inosine and 
its structure as ribofuranoside 5’-monophosphate was de-
scribed by P.A. Levene & R.S. Tipson 88 years later (Scheme 
1) [1]. It is interesting to note that it was P.A. Levene who 
coined the general term “nucleotide” for phosphoric acid de-
rivatives formed as the result of nucleic acid hydrolysis, and 
suggested the term “nucleoside” for dephosphorylated nu-
cleotides, and also identified D-ribose and later 2-deoxy-D-
ribose as constituents of RNA and DNA, respectively [2 – 7]. 
Pioneering structural studies on nucleosides and nucle-
otides during the last decade of the 19th and first decade of 
the 20th centuries showed that DNA and RNA consist of five 
heterocyclic bases and two pentoses. The first chemical con-
densation of these two of two components was reported by 
E. Fischer & B. Helferich in 1914 [8]; condensation of a sil-
ver salt of 2,8-dichloroadenine with 2,3,4,5-tetra-O-acetyl-
α-D-glucopyranosyl bromide followed by deprotection and 
hydrodehalogenation yielded a  nonnatural nucleoside N9-
(β-D-glucopyranosyl)adenine (10), whose structure was un-
equivocally proved by J.M. Gulland & L.F. Story 24 years 
later (Scheme 1) [9]. Between World War I and II, a number 
of very important studies dedicated to the chemical synthe-
sis of pyrimidine and purine nucleosides were published, but 
systematic studies on the chemical synthesis of nucleosides, 
nucleotides, and oligomers were started by A. Todd and his 
co-workers in 1942 at Cambridge University in England and 
somewhat later in the USA. Since then, numerous books and 
reviews have been published on the subject, summarizing the 
enormous progress achieved (see [10 – 12]). 
Systematic studies of the biological properties of nucle-
osides began in the second half of the 1940s. Somewhat ear-
lier, P. Fildes & D.D. Woods formulated the antimetabolite 
theory and a resulting approach to the design of natural com-
pound analogs with biomedical potential sparked an enor-
mous amount of research in this area (for the relevant re-
views, see [13, 14]). Despite the moderate predictive power of 
this theory, synthesis of a large variety of natural nucleoside 
analogs and data on their biological properties yielded (i) very 
useful tools for studying biochemical transformations, which 
facilitated understanding of the mechanism of functioning of 
enzymes of nucleic acids metabolism; (ii) an analysis of the 
structure-activity relationships, which allowed rational de-
sign of new analogs with improved activity-toxicity ratios; 
and (iii) a number of anticancer and antiviral drugs. 
Thirty years of systematic studies resulted in the discovery 
of several major structures of great biological and medicinal 
importance, such as heterocyclic bases (6-mercaptopurine 
(11), thioguanine (12), 5-fluorouracil (13)), analogues of thy-
midine modified at C5 of an aglycone (2′-deoxy-5-iodouridine 
(14), Idoxuridine,; Iduviran;, 2′-deoxy-5-fluorouridine (15), 
FUDR, Floxuridine; (E)-5-(2-bromovinyl)-2′-deoxyuridine 
(16), BVDU, Brivudine) and at C3′ of the carbohydrate moi-
ety (3′-deoxy-3′-fluorothymidine (17), FLT, Alovudine and REVIEWS
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3′-deoxy-3′-azidothymidine (18), AZT, Zidovudine), β-D-
arabinofuranosyl nucleosides (1-( β -D-arabinofuranosyl)-
cytosine (19), aC, Cytarabine; -adenine (20), aA, Vidarabine; 
-guanine (21), aG), 3-carboxamido-1-( β -D-ribofuranosyl)-
1,2,4-triazole (22), Virazole, Ribavirin, hyper-modified purine 
acyclonucleosides, and also analogs in which the sugar moiety 
of a nucleoside is replaced with an aliphatic chain mimick-
ing the carbohydrate fragment, such as Aciclovir (23), ACV, 
Zovirax; Gancyclovir (24), DHPG, Cytovene; Buciclovir (25), 
Penciclovir (26), and Famciclovir (27)  (Scheme 2). 
Discovery of a number of compounds that displayed strong 
antiviral and/or anticancer activities, some of which were 
later approved by the FDA (Food and Drug Administration, 
USA), as well as isolation of nucleoside antibiotics from natu-
ral sources [15], stimulated extensive synthesis of a wide va-
riety of modified nucleosides. Studies aimed at shedding light 
on the mechanisms behind the antiviral and antitumor activi-
ties of these compounds yielded extensive data regarding the 
metabolic transformations of modified nucleosides, including 
their metabolic activation and deactivation. Moreover, these 
studies identified the enzymatic reactions involved in these 
activities, and also led to the discovery of the role of nucle-
oside utilization mechanisms (“salvage” synthesis) and the in-
volvement of virus-encoded nucleoside kinases in a key step 
of nucleoside activation via intracellular 5′-monophosphor-
ylation. The nucleoside-5’-monophosphates are then further 
metabolized into 5’-di- and 5’-triphosphates, which can then 
take part in various metabolic transformations [14, 16 – 19]. 
It was established that the majority of nucleoside analogs 
exhibiting antiviral and/or antitumor activities are not ac-
tive as such but gain activity after being transformed into 
nucleotides by intracellular enzymes. In the case of antiviral 
agents, nucleoside-5’-triphosphates are often true inhibitors 
of viral DNA or RNA polymerases. In some cases, polymerases 
introduce an analog of the natural substrate into the growing 
chain, thus blocking or severely impeding the chain’s growth 
or producing a functionally incompetent biopolymer [16, 17]. 
In cancer cells, synthesis of the active species is initiated 
either by the transformation of a heterocyclic base into the 
respective ribonucleoside-5′-monophosphate, catalyzed by 
nucleoside phosphoribosyl transferase or by direct 5′-mono-
phosphorylation of nucleosides by cellular nucleoside kinas-
es [14, 20 – 22]. On the contrary, in virus-infected cells, the 
first critical step of antiviral nucleoside activation involves 
5′-monophosphorylation catalyzed by virus-encoded kinases 
[16, 17, 23]. 
Catabolic deactivation of biologically active nucleosides of-
ten involves deamination of cytosine and adenine nucleosides 
by the respective deaminases, which usually yield inactive 
derivatives [14, 24, 26], and phosphorolytic cleavage of the 
glycoside bond by nucleoside phosphorylases, which results 
in the formation of heterocyclic bases and α-D-pentofuranose 
1-phosphates [24, 27 and works cited in 27]. 
New data on the metabolism of nucleosides and their 
mechanism of action towards their targets allowed improve-
ment of the activity of the originally discovered compounds 
by protecting them from catabolic transformations and facili-
tating their targeted delivery, and also stimulated the search 
for new biologically active molecules [18, 19, 28]. The first ap-
proach can be illustrated by the  anticancer drugs Ftorafur® 
(28), 5-fluoro-5’-deoxyuridine (29), and Capecitabine (30); by 
nucleosides similar to aA, such as Cladribine (31), Fludarab-
ine (32) and Clofarabine (33), which are highly active against 
various forms of leukemia and are resistant to deamination by 
adenosine deaminase [21, 22]; and by the antileukemic drug 
Nelarabine (34), “prodrug” aG, which has better solubility 
and stronger activity as compared to the parent aG drug [29] 
(Scheme 3). 
Elucidation of the mechanism of AZT action and establish-
ment of viral-encoded reverse transcriptase as an important 
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biochemical target for anti-HIV drugs stimulated extensive 
synthesis of various 2′,3′-dideoxy nucleosides, e.g., Zalcitabine 
((41); Hivid®),  Didanosine (42) and related nucleosides with a 
C2′-C3′ double bond, 2’,3’-didehydro-2’,3’-dideoxythimidine 
((35), Stavudine, Zerit®) and its cytosine analogs ((36), (37); 
Reverset™), nucleosides with oxygen or sulfur atoms substi-
tuting the C3’ carbon atom of the pentofuranose ring ((38), 
Amdoxovir; (39), Lamivudine, Epivir®; (40), Emtricitabine, 
Emtriva®), as well as a number of hypermodified acyclic nu-
cleosides with phosphonate function and their prodrugs ((43), 
Cidofovir; (44), Tenofovir) [30 – 34] (Scheme 3). 
Notably, pioneering studies by H. Schaeffer and co-
workers on the synthesis and study of the biochemical 
properties of acyclic nucleosides led to the discovery of 
9-[2-hydroxy(ethoxymethyl)]guanine ((23), Acyclovir) as an 
effective antiviral drug [35 – 38] and stimulated extensive 
synthesis of a wide variety of acyclic nucleosides modified 
either in the aglycone or in the acyclic fragmentt, including 
phosphonate analogs of nucleoside 5′-phosphates and their 
numerous prodrugs, some of which manifested a broad spec-
trum of biological activities [39]. 
Up to the present, a vast majority of the modified nucle-
osides have been synthesized by chemical methods. Most of 
the developed synthetic approaches can be divided into three 
main groups: (i) convergent synthesis, employing the suitable 
sugar or sugar-mimicking derivatives as glycosylating agents, 
(ii) chemical transformations of natural nucleosides, and (iii) 
rational combinations of both aforementioned approaches. 
Despite the impressive progress achieved in the development 
of chemical methods, production of many antiviral and anti-
cancer drugs, as well as other biologically active compounds, 
remains a challenge. This leads to high drug costs and con-
sequently prevents extensive biological trials and studies, as 
well as broad therapeutic application. The need for the devel-
opment of new strategies became apparent in the late 1970s.
CHEMO – ENZYMATIC STRATEGY FOR THE SYNTHESIS 
OF NUCLEOSIDES (NUCLEOSIDE BIOTECHNOLOGY)
Amidst the great number of nucleic acid metabolism en-
zymes, approximately 20 are promising in relation to the de-
velopment of novel effective strategies for the production 
of biologically important nucleosides. These are foremostly 
enzymes that catalyze the condensation of heterocyclic bases 
and sugars, thus forming glycoside bonds, and also enzymes 
that are involved in various transformations of nucleosides. 
These enzymes are of utmost importance for the research and 
development of novel approaches for nucleoside synthesis.
In parallel with the pioneering chemical studies and in-
vestigation of the biochemical properties of modified nucle-
osides, researchers began attempting the isolation of enzymes 
involved in nucleic acid metabolism from natural sources and 
to study the mechanisms of their functioning (for a review, 
see [24]). The first reports by P. Levene and co-workers [40 – 
44] and W. Jones [45, 46] on the activities involved in nucleic 
acid hydrolysis and nucleoside disassembly were published in 
1911; later on, Levene and co-workers described a procedure 
for the isolation of “nucleosidase” from the spleen, kidney, 
and pancreas of cattle. The isolated enzyme was able to hy-
drolyze adenosine and inosine in phosphate buffer with simi-
lar efficiency, thus yielding the respective bases and ribose 
(formation of ribose-1-phosphate was not discovered at that 
time!). The authors also investigated the properties of this en-
zyme [47 – 49]. They determined the optimal temperature (37 
°C) and pH (7.5) of the reaction and found that (i) ribose and 
adenine exert “an impeding influence on the progress of the 
reaction,” (ii) kaolin completely adsorbs the partially purified 
enzyme from the solution, and the enzyme-kaolin complex  is 
stable within pH 4.0 – 8.0 values at 40 °C for 15 h and shows 
the same level of activity, (iii) a chemically prepared adenine 
nucleoside containing hexose (the structure was not estab-
lished) could not act as a substrate for this enzyme. 
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Later on, H. Kalckar investigated nucleosidase extracted 
from rat liver and found that (i) this enzyme was in fact a 
purine nucleoside phosphorylase (PNP; EC 2.4.2.1), which hy-
drolyzed inosine or guanosine via phosphorolysis, thus yield-
ing ribose-1-phosphate (structure was later determined to be 
α-D-ribofuranose-1-O-phosphate; RP; (47); for reviews, see 
[24, 50]) and the corresponding purine bases, hypoxanthine 
or guanine; (ii) when RP is incubated with hypoxanthine or 
guanine in the presence of PNP, a rapid formation of inosine 
or guanosine takes place [51, 52]. Kalkar’s paper was the first 
report on the isolation of pure RP. Shortly after this publica-
tion, L. Manson & J. Lampen showed that quiescent Esheri-
chia coli cells, as well as a cell-free extract, contain enzymes 
which can hydrolyze 2′-deoxyinosine and thymidine in the 
presence of inorganic phosphate down to free bases and a de-
oxyribose ester whose structure was later established to be 
2-deoxy-α-D-ribofuranose-1-phosphate (48) [24, 53]. It was 
suggested that this extract contains purine and pyrimidine 
nucleoside phosphorylases, whose specificity was later found 
to be similar to that of mammalian enzymes. Moreover, evi-
dence was presented that these bacterial enzymes reversibly 
catalyze the synthesis of nucleosides and their phosphorolytic 
degradation (Scheme 4). 
Subsequent studies have corroborated and extended these 
fundamental findings, and it was found that purine nucleo-
side phosphorylase is specific to 9-(β-D-pentofuranosyl)pu-
rines, whereas mammalian PNP is specific to 6-oxopurines 
(compared with data by Levene et al. [47 – 49]; vide supra) 
and their nucleosides, as well as some analogs, whereas PNP 
from bacterial sources displays very broad specificity, accept-
ing both 6-oxo- and 6-aminopurines and their nucleosides as 
substrates, along with many analogs. 
Thymidine phosphorylase (TP; EC 2.4.2.4) reversibly cata-
lyzes the phosphorolysis of thymidine (7) and 2′-deoxyuridine 
but not uridine (7) or 1-(β-D-arabinofuranosyl)-thymine and 
–uracil, whereas uridine phosphorylase (UP; EC 2.4.2.3) does 
not distinguish between β-D-ribofuranose and 2′-deoxy-β-D-
ribofuranose in pyrimidine nucleosides and accepts 1-(β-D-
arabinofuranosyl)-pyrimidines as substrates as well. Cytosine 
and its nucleosides are not substrates either for TP or UP; 
however, we must note two peculiar observations. Firstly, 
PNP exhibited cytidine phosphorylase activity in some ex-
periments [54]. Secondly, it was shown that human deoxycy-
tidine kinase is a cytosolic enzyme that plays a key role in the 
activation of therapeutically relevant nucleoside analogs via 
their 5’-monophosphorylation, accomplishes phosphorolytic 
cleavage of 2’-deoxynuclosides, including 2′-deoxycytidine 
into free heterocyclic bases and 2-deoxy- α-D-ribofuranose-
1-phosphate [55].
The results of pioneering research unequivocally indicated 
a possibility for the enzymatic synthesis of nucleotides us-
ing purine or pirimidine heterobases as a starting point and 
Scheme 3
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α-D-pentofuranose-1-phosphate or another nucleoside as a 
carbohydrate fragment donor (see [24, 56] for a review). The 
first attempts to use enzymes for the synthesis of pyrimidine 
nuclesides were made by M. Friedkin & D. Roberts, who at-
tempted to synthesize thymidine and related nucleosides [57, 
58], and by R. Duschinsky & C. Heidelberger for the synthesis 
of 5-fluoro-2′-deoxyuridine (FUDR, (15)) and 2′-deoxy-β-D-
ribofuranosil-5-trifluoromethyl-urcail (CF3-dUrd) [59–64]. 
Interestingly, the first report of FUDR synthesis via enzy-
matic transfer of the 2-deoxyribofurnaose residues of thy-
midine onto 5-fluoro-uracil (13) was published in 1957 [59]. A 
preparative-scale enzymatic process was later patented [60]. 
The same group of researchers described a chemical meth-
od for the synthesis of 5-fluoro-2’-deoxyuridine (15), and 
a low-yield enzymatic process for the synthesis of another 
anti-cancer nucleoside – CF3-dUrd using a cell-free extract 
of E. coli as a source of thymidine phosphorylase [36] (See 
[24, 56, 65–68] for reviews). Later on, a number of 5-modi-
fied uracil nucleosides, including 2′-deoxy-5-iodouridine 
((14); 55%), 5-fluoro-2′-deoxyuridine ((15); 65%), and Е-5-
(2-bromovinyl)-2′-deoxyuridine ((16); 61%), were obtained 
by using thymidine (3) or 2′-deoxyguanisone (2) as donors of 
2-deoxyribofuranose, the appropriate heterobases as accep-
tors, and selected BM-11 E. coli as a biocatalyst [69].
Transfer of a pentofuranose moiety from pyrimidine 
nucleosides to purine bases and vice versa (transglycosyla-
tion reaction) catalyzed by bacterial nucleoside phospho-
rylases (NP) was shown to be a very efficient method for 
the synthesis of a number of analogs of natural purine and 
pyrimidine nucleosides of biological and pharmaceutical im-
portance. The most exploited pathway includes the transfer 
of a pentofuranase moiety from pyrimidine nucleosides to 
purine bases (Scheme 5). 
This transglycosylation approach is based on numerous ef-
ficient chemical transformations of readily available natural 
pyrimidine nucleosides into diverse nucleosides modified in 
their carbohydrate component through the intermediate for-
mation of O2,2′(3′;5′)-anhydro derivatives, followed by open-
ing of the anhydro ring upon treatment with nucleophilic 
agents. Unfortunately, a similar approach is not practical for 
the production of related purine nucleosides. Moreover,  dis-
tinctions in the substrate specificity of TP and UP extend the 
number of the pentofuranose donors of the transglycosyla-
tion reaction that can be used with the optimal efficiency. 
Thus, 1-(2-deoxy-2-fluoro-β-D-ribofuranosyl)uracil (Scheme 
5, X = Y = OH; Z = riboF) and 1-(2-deoxy-2-fluoro-β-D-
arabinofuranosyl)thymine (Scheme 5, X = Y = OH; Z = arab-
inoF) display no substrate activity towards UP: thus it cannot 
be employed as a biocatalyst; on the contrary, both nucle-
osides have been found to be (although very poor) substrates 
for TP, allowing their use for TP-catalyzed transglycosylation 
of purine bases [70, 71]. 
The successful employment of nucleoside phosphorylases 
as biocatalysts for the synthesis of purine arabinosides and a 
multitude of base- and carbohydrate-modified nucleosides 
has been described in numerous publications (for reviews, 
see [24, 56]). 
Three types of biocatalysts have been successfully em-
ployed for transglycosylation reactions: (i) selected intact 
bacterial cells, which display UP and/or TP and PNP activi-
ties, (ii) intact bacterial cells overexpressing recombinant 
nucleoside phosphorylases, and (iii) purified recombinant 
enzymes. 
Intact bacterial cells as a biocatalyst represent a kind of 
naturally immobilized enzyme, which can be used for the 
transformation of interest. Use of this type of biocatalysts of-
fers some advantages (relatively low cost) over the applica-
tion of purified enzymes or immobilized (encapsulated) en-
zymes. However, intact bacterial cells may display activities 
which will catalyze the transformation of the substrate and/
or the desired product of the transglycosylation reaction into 
an undesirable form (see further). On the other hand, consid-
erable progress has been achieved in the practical production 
of recombinant enzymes during the last decade, which makes 
these biocatalysts available for broad application, including 
the development of biotechnological processes for the pro-
duction of drugs. In case of very low substrate activity of a 
pentofuranose donor or an acceptor base, use of purified en-
zymes as biocatalysts may be a rational alternative to the use 
of intact bacterial cells. 
Notably, the off-pathway activities displayed by intact 
cells can be rationally involved in the synthesis of the desired 
nucleosides. For example, selected E. coli BM-11 cells display-
ing high cytidine deaminase (CDase) activity, along with UP 
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and PNP activities, were employed as a biocatalyst for the 
synthesis of aG (21) (isolated yield 48-53%) using aC (19) and 
2′-deoxyguanosine ((2); dGuo) as donors of D-arabinofuran-
ose residue and in situ formed guanine ((51); Gua), respec-
tively (Scheme 6). Deamination of aC to aU (49) by cytidine 
deaminase precedes the formation of α-D-arabinofuranose-
1-phosphate (50) from aU catalyzed by UP. 
A similar approach was employed for the synthesis of 
2′-deoxy-2′-fluoroguanosine using 2′-deoxy-2′-fluorocytidine 
as a donor of 2-deoxy-2-fluoro-α-D-ribofuranose-1-
phosphate [73]; note that the use of selected E. coli BMT-
4D/1A cells for the synthesis of 2′-deoxy-2′-fluoroguanosine 
[73] appears to be preferable over the use of purified UP and 
PNP [70, 71]. 
The use of the selected E. coli cells was found to be very 
efficient for chemoenzymatic syntheses of purine 3′-amino-
2′,3′-dideoxy-β-D-ribonucleosides (Scheme 7) [74]. Notably, 
AZT (18) is neither a substrate for TP or UP and cannot, 
therefore, be used as a donor of the pentofuranose moiety. 
Reduction of the azido group of AZT produces 3′-amino-
2′,3′-dideoxythymidine ((52); dThd3’NH2) that is a satisfactory 
substrate for TP and can be used as a donor of the carbohy-
Scheme 6
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drate moiety. Transfer of the pentofuranose moiety from 
dThd3’NH2 to adenine catalyzed by intact E. coli cells proceeds 
smoothly, and the desired 3′-amino-2′,3′-dideoxyadenosine 
((54); ddAdo3’NH2) can be isolated with good yields. Howev-
er, replacement of adenine (53) by N6-benzoyladenine (56) 
in the aforementioned reaction produces 3′-amino-2′,3′-
dideoxyadenosine (54) instead of the expected N6-benzoyl 
derivative of ddAdo3’NH2 (57), owing to the off-pathway activ-
ity present in the intact cells.
Taking into account that ddAdo3’NH2 with orthogonally pro-
tected amino functions (58) is of interest for oligonucleotide 
synthesis, we recently investigated transglycosylation reac-
tions using pure recombinant E. coli TP and PNP [75]. It was 
found that the use of Thd3’NH2 as a donor of the pentofuranose 
residue and TP and PNP as biocatalysts or a dGuo3’NH2 / PNP 
combination (5 mМ K-phosphate buffer (рН 7.0), 50 °С, 24 h) 
produced the desired N6-benzoyl derivative of ddAdo3’NH2  
(57) in high yield (Scheme 7) [76]. Standard treatment of the 
latter with Fmoc-OSU yielded the desired ddAdoBz
3’NHFmoc (58) 
with orthogonally protected amino groups.
The possible areas of application of nucleoside phosphory-
lases for the synthesis of nucleosides, as well as the limitations 
of this methodology, have been investigated in detail; how-
ever, several very interesting enzymatic synthetic reactions 
deserve special attention, because they are crucial for under-
standing the mechanism of synthetic reactions catalyzed by 
these enzymes and may expand the scope of their practical 
use.
It is well documented that the N7-atom of purine plays 
a very important role in the phosphorolytic cleavage of the 
glycosyl bond of purine nucleosides ([77, 78] and works cited 
in [77]) and, it seems, in the reversed synthetic reaction cata-
lyzed by E. coli PNP as well, even though the mechanism of 
this reaction has not been adequately studied. The finding 
that 3-deazapurines [79 – 81] and 1-deaza-, 3-deaza- and 
1,3-dideazapurines (benzimidazoles, including fluoro-, chlo-
ro- and bromo-substituted) [82 – 84] are good substrates for 
E. coli PNP allows the authors to suggest a key role for two 
nitrogen atoms of the imidazole ring in the above-mentioned 
reaction. Namely, one of them is involved in the binding of the 
heterocyclic base in the enzyme’s active site, which may in 
turn increase the nucleophilicity of the second nitrogen atom. 
This facilitates an attack by this atom on the electrophilic C1 
carbon atom of α-D-pentofuranose-1-phosphate and eventu-
ally results in the formation of a glycosidic bond (Scheme 8).
Remarkably, the mechanism of this synthetic reaction 
catalyzed by nucleoside phosphorylases did not attract the 
attention of researchers and many important details were left 
unclear. Thus, the mode of initial binding of the substrate or 
inhibitor of E. coli PNP (see binding types A and B in Scheme 
8) might have shed light on the mechanism of the enzyme’s 
functioning and provided a clue for the explanation of some 
unusual observations. Participation of two nitrogen atoms in 
this reaction seems obvious taking into account the fact that 
7-deazahypoxanthine ((61); 7-DAH) is a very potent inhibitor 
of PNP (Scheme 8) [50, 85]. Tubercidine (59) and 7-deazai-
nosine (60) are not substrates for PNP and showed very low 
affinity for the active site of the enzyme. On the contrary, the 
free base, 7-deazahypoxanthine (61), is recognized by the en-
zyme and forms a very strong PNP-phosphate-base complex, 
which results in complete inhibition of the enzyme [85]. 
The mechanism of 7-DAH binding in the E. coli PNP bind-
ing site still remains unknown; two types of interactions can 
be proposed – А and В. The first (type A) is similar to one of 
the two possible modes of binding of the natural substrate 
in the PNP active site via a hydrogen bond with the car-
boxyl moiety of aspartic acid-204 (type А on Scheme 8 and 
type A on Scheme 9). Obviously, type A binding of 7-DAH 
in the E. coli PNP binding site cannot result in the formation 
of a nucleoside, since there is no N9-nitrogen atom (purine 
numbering). Type В binding involves the formation of an 
unusual hydrogen bond between the ОН-group of the tau-
tomeric form of the cyclic amide. This hypothetic bond can 
seemingly stabilize the PNP–phosphate–7-DAH complex 
Scheme 8REVIEWS
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(N9-H-structure), whose electron or spatial structure either 
impedes or prevents a nucleophilic attack of the C 1-atom of 
α-D-pentofuranose-1-phosphate (47) (Scheme 9). The hypo-
thetical possibility of the existence of a В-type structure is 
unexpectedly supported by the moderate acceptor activity 
of 5-aza-7-deazaguanine (62) during a glycosylation reaction 
involving PNP (bovine spleen extract; Sigma) and   2-deoxy-
β-D-pentofuranose-1-phosphate (48) as a carbohydrate do-
nor (see [86] and other works cited in this article). Indeed,  the 
heterobase can exist in three tautomeric forms (62-I–III), and 
one of them, a (62-III) structure, can be recognized by PNP 
and thus result in the formation of a nucleoside via a nucleo-
philic attack of the free N9-nitrogen atom on the C 1-carbon 
atom of the carbohydrate substrate (Scheme 10). Notably, 
analysis of tautomeric structures involving ab inito (6-31G**) 
and semi-empirical methods (PM3, in water) (HyperChem 
8.1) show that structure II is the most stable in terms of ther-
modynamics, while structures III and I are less stable (I.A. 
Mikhailopulo, unpublished).
Obviously, the binding mechanism of 7-DAH and 5-aza-7-
deazaguanine (62) in the PNP active site and also the possi-
ble ways of using this information for the production of some 
7-deazopurine-derived nucleosides deserve further thorough 
research.
Other examples of unusual biotransformations are the 
metabolic and enzymatic transformations of the anti-influen-
za agent N-(1,3,4-thiadiazol-2-ylc)yanamide ((64); LY217896) 
(Scheme 11) [87, 88]. This compound shows a degree of struc-
tural similarity with the heterocyclic bases of the antiviral 
nucleoside Virazole ((22); Ribavirin) and of the anticancer C-
nucleoside tiazofurin (65). It was found to be active against 
the influenza A and B viruses both in vitro and in animal 
models but was ineffective in clinical trials against an experi-
mental influenza A (H1N1) virus. A number of its metabo-
lites were detected in experiments with mammalian cells and 
animals as well, and the structures of three metabolites were 
established (Scheme 11).
It was found that purine nucleoside phosphorylases isolat-
ed from calf spleens and human erythrocytes, as well as  the 
bacterial enzyme (Sigma, N-8265), catalyze the transforma-
tion of N-(1,3,4-thiadiazol-2-yl)cyanamide in the presence of 
α-D-ribofuranose-1-phosphate (47) into N4- and N3-ribosides 
(37 °C, 20-70 h, 2 – 200 units of PNP; the ratio between the 
N4- and N3-ribosides ((66) and (67)) was found to be ~ 1:3 (60-
65% combined yield) at high concentrations of PNP and ~ 3:1 
(12-14% combined yield) at low concentrations of PNP) [89]. 
Interestingly, the formation of the mesoionic [88] or ionic (as 
Scheme 9
Scheme 1044 | ACTA NATURAE |  VOL. 2  № 2 (5)  2010
REVIEWS
shown in Scheme 11) N4-riboside (66) apparently proceeded 
in an irreversible manner, whereas the N3-riboside (67) was 
found to be a substrate of PNP. 
We must also mention several extremely interesting ob-
servations made in this excellent study. Firstly, 1,3,4-thiadia-
zol-2-ylcyanamide displayed broad antiviral activity in vitro 
and in animal models against orthomyxo- and paramyxovi-
ruses. Oral, intraperitoneal or aerosol administration of the 
drug protected mice against lethal influenza A or B virus 
infections; however, it did not show either toxicity or anti-
influenza activity in phase I trials on healthy volunteers [89]. 
Secondly, the data on the pharmacokinetics of the thiadiazol 
base also show considerable diversity. Thirdly, contrary to 
the above, PNP of mammalian and bacterial origin manifest-
ed close catalytic similarity in the ribosylation of this base, 
despite the well-known differences between the substrate 
preferences of these two types of PNP for natural substrates. 
These data imply that N-(1,3,4-thiadiazol-2-yl)cyanamide 
(64), which does not have any common features with natural 
substrates of PNP, still possesses functionality that is suf-
ficient for the synthetic reaction catalyzed by both types of 
PNP. Testing new heterocyclic bases as substrates of PNP 
may help understand this functionality, providing further 
insight into the mechanism of the enzyme’s function and also 
opening new possibilities for its practical use.
The use of intact bacterial cells as a biocatalyst for transg-
lycosylation reactions (Scheme 5) implies that the cells contain 
uridine, thymidine, and purine nucleoside phosphorylases. 
Besides the aforementioned nucleoside phosphorylases, other 
phosphorylases have been found in bacteria that may be use-
ful for the enzymatic synthesis of nucleosides. For instance, 
the nucleoside phosphorylase purified from the Klebsiella sp. 
strain LF1202 demonstrated very interesting properties [90]. 
It consists of five identical subunits with a molecular weight 
of 25 000 Da (based on the results of SDS-PAGE) and shows 
pyrimidine and purine nucleoside phosphorylase activities. 
Inosine, adenosine (5), 2′-deoxyadenosine (1), guanosine (6), 
and 2′-deoxyguanosine (2) showed similar substrate activity 
(relative activity ~100%) in phosphorolysis (Km values for ino-
sine and inorganic phosphate (Pi) were calculated to be 0.66 
and 0.56 mM, respectively); substrate activity for 2′-deoxyi-
nosine was 2.5-fold higher (254%); xanthosine and its 2′-deoxy 
counterpart did not act as substrates. In the synthetic reac-
tion, the substrate activity of hypoxanthine and adenine was 
similar (Km values for hypoxanthine and α-D-ribofuranose-
1-phosphate ((47); α-D-RF-1P) were calculated to be 0.45 
and 0.14 microM, respectively); guanine showed somewhat 
decreased substrate activity in the synthetic reaction. As for 
pyrimidine nucleosides, uridine was found to be the best sub-
strate (relative activity 368%) as opposed to 2′-deoxyuridine 
(95%) and thymidine (29%); the Km values for uridine (0.38 
mM) during phosphorolytic cleavage and for uracil (0.44 mM) 
during the synthetic reaction were similar. The substrate 
activity of uracil in the synthetic reaction with α-D-RF-1P 
(82%) and 2-deoxy-α-D-ribofuranose-1-phosphate (48) was 
found to be 82 and 39%, respectively; thymine showed de-
creased activity (17%); neither cytidine, nor 2′-deoxycytidine, 
nor cytosine demonstrated any substrate activity in the enzy-
matic reactions. 
The Klebsiella sp. nucleoside phosphorylase was employed 
for the synthesis of aA from aU and adenine (3:1 molar ra-
tio) under optimized reaction conditions (0.1 M K-phosphate 
buffer, pH = 8.0; 6.7 mM concentration of adenine; 50 °C, 30 
h; 0.86 units of enzyme) and converted approximately 90% of 
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the adenine into aA, as assayed by TLC analysis of the reac-
tion mixture [90].
H. Shirae & K. Yokozeki isolated an orotidine-phosphoro-
lysing enzyme (OrP) from Erwinia carotovora AJ 2992 and 
investigated its properties [91]. Orotidine (OrP) was irrevers-
ibly phosphorolysed into orotic acid and 1-phosphate (47) by 
OrPE, and the enzyme showed no strict specificity. Indeed, 
the substrate activity of uridine was found to be two orders 
of magnitude higher as opposed to orotidine (relative activ-
ity of 100% and 1% for uridine and orotidine, respectively); 
moreover, 5-methyluridine (10%), aU (11%), 2′-deoxyuridine 
(22%), 3′-deoxyuridine (11%), and 2′,3′-dideoxyuridine (1%) 
were also found to be substrates for the OrP preparation. At 
each purification step, OrPE was always co-purified with uri-
dine phosphorylase (UP) and the researchers were unable to 
separate these two activities. Both activities corresponded 
to a single band on SDS-PAGE, suggesting that both activi-
ties are present in the same protein. The purified enzyme had 
a molecular weight of 68 000 ± 2 000 Da, which suggests a 
dimeric structure. The most interesting finding is that the 
optimal temperatures and the pH values of the phosphate 
buffer were found to be 60 °C and 6.0 for orotidine phospho-
rylase activity and 70 °C and 7.0 for the uridine phosphorylase 
activity. On the whole, despite the differences in the optimal 
conditions for these two activities, it appears that the enzyme 
preparation from Erwinia carotovora AJ 2992 consists of a UP 
with broad substrate specificity. 
N-Deoxyribosyltransferases (DRT’s; nucleoside: 
purine(pyrimidine)deoxyribosyl transferases; EC 2.4.2.6) rep-
resent another type of enzymes, which are considerable in-
terest as biocatalysts for nucleoside synthesis (for a review of 
pioneering studies, see [92]). As opposed to nucleoside phos-
phorylases, DRTs catalyze the direct transfer of the deoxy-
ribofuranosyl moiety between a nucleoside and an acceptor 
base without intermediary formation of 2-deoxyribofuranose 
phosphate. The reaction proceeds through the intermediate 
formation of a covalently bound 2-deoxy-α-D-ribofuranosyl 
moiety, whose glycosidic hydroxyl forms a complex ester bond 
(Scheme 12) [93 and works cited in this paper].
DRTs are mainly present in some bacterial species of the 
Lactobacillus genus and were first discovered by W.S. Mac-
Nutt [94] in Lactobacillus helveticus and isolated by A. Roush 
& R. Betz [95]; later, DRT was purified from L. leichmannii 
by W. Beck & M. Levin, and its properties were thoroughly 
studied [96]. Lactobacillus bacteria contain DRT enzymes 
with two types of enzymatic activity, and these were first 
isolated by L. Holguin & R. Cardinaud  from L. helveticus us-
ing affinity chromatography: DRT class I (also called purine 
deoxyribosyltransferase, PDT),  which specifically transfer 
2-deoxyribofuranose moieties from purine nucleosides to 
purine bases, and DRT class II (also called nucleoside deox-
yribosyltransferase, NDT), which catalyze the transfer of 
2-deoxyribofuranose between purines and pyrimidines in any 
combination [97]. Early reports on DRT substrate specificity 
revealed (i) strict specificity for the 2-deoxyribofuranose moi-
ety, the absence of β-D-ribonucleoside substrate activity[92]; 
(ii) rather broad tolerance regarding various modifications 
of natural purines [96, 98, 99]; (iii) good substrate activity of 
cytosine as an acceptor of the 2-deoxy- and 2,3-dideoxyribo-
furanose residues, and the corresponding purine and pyrimi-
dine nucleosides as donors of carbohydrate moieties [100] (for 
a review, see [24]).
A number of very interesting observations concerning 
the possible practical applications of DRT were made dur-
ing the last two decades. Thus, D.A. Carson & D.B. Wasson 
investigated the substrate specificity of NDT isolated from 
L. helveticus (ATCC, #8018) (purified according to [96]) and 
found that the enzyme displays broad specificity both for 
pentofuranose residue donors and for purine and pyrimidine 
acceptors [100]. Testing the pentofuranose donor activity of 
2′,3′-dideoxy-β-D-nucleosides (ddN) in acetate buffer (pH 
6.0) with an equimolar ratio between the donor and accep-
tor molecules at 37 °C revealed an exceptionally high activity 
of cytosine as an acceptor (16-60 nmol·min-1·mg-1 of enzyme 
with the following preference for donors: dT > ddG > ddC 
> ddA > ddI); donor activity of 2′,3′-dideoxycytidine (ddC) 
and 3′-deoxythymidine (dT) was found to be approximately 
2.2-11.6 nmol·min-1·mg-1 of enzyme for adenine, guanine, and 
hypoxanthine acceptors. 
The first recombinant L. leichmanii NDT (DRT II) was 
prepared by W. Cook et al. [101]. These authors also studied 
the biochemical properties of this enzyme [102-104] and es-
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tablished the architecture of the enzyme’s active site [105]. 
In its native state, the enzyme turned out to be a hexamer 
composed of identical subunits with one active site per sub-
unit, and two subunits forming a complete catalytic center. 
R. Wolfenden and co-workers discovered a lyase activity of 
L. leichmanii NDT and found that an interim 1-O-glutamyl 
derivative of 2-deoxy-D-ribofuranose is broken down in the 
absence of a heterocyclic base, yielding D-ribal. The latter 
reacts with adenine in a stereospecific manner under NDT 
catalysis, forming 2′-deoxyadenosine in aqueous solution 
and its 2’-α-deuterium derivative in D2O (Scheme 13) [102]. 
Formation of thymidine and 2’-deoxyuridine from D-ribal 
and the respective bases could also be performed in a similar 
manner. The practical implications of this study of the chem-
oenzymatic synthesis of 2′-β-D-deoxynucleosides have not 
yet been investigated; however, further studies in this di-
rection seem practical, as D-ribal can readily be produced 
by chemical methods (see [106, 107]), and the recombinant 
enzyme is also available. 
Notably, recombinant L. leichmanii NDT catalyzes the 
stero- and regioselective transfer of 3-azido-2,3-dideox-
yribofuranose from AZT to various 2-amino-6-substituted 
purine bases (50 mM Na-citrate buffer, pH 6.0; 50 °C, 21-28 
days) yielding the corresponding purine N9-β-D-nucleosides 
with moderate yields. The same enzyme was also employed 
as a biocatalyst for the synthesis of purine 4′-thionucleosides 
[104]. 2′-Deoxy-4′-thiouridine (used as an anomere mixture 
obtained via chemical glycosylation of uracil) was used as a 
carbohydrate moiety donor for the transglycosylation of a 
number of purine bases, with NDT as a catalyst (50 mM cit-
rate buffer, pH 6.0; 50 °C, 5 days). Individual 9-(2′-deoxy-4′-
thio-β-D-ribofuranosyl) purines were isolated with yields in 
the range of 5-48% after laborious treatment and chroma-
tography of the reaction mixtures. It is worth noting that the 
use of thymidine and purine nucleoside phosphorylases as 
biocatalysts for the transglycosylation reaction yielded nega-
tive results. 
Identification of glutamic acid 98 as the active site nucle-
ophile of recombinant L. leichmanii NDT (the DRT II class) 
was made by D. Porter et al. [108]. The authors thoroughly 
investigated the interaction of the enzyme with 4 isomeric 
pairs of nucleosides, namely 9-(2-deoxy-2-fluoro-β-D-
ribo(arabino)furanosyl)adenine ((71) and (72)), 2-amino-9-
(2-deoxy-2-fluoro-β-D-ribo(arabino)furanosyl)adenine ((73) 
and (74)), 1-(2-deoxy-2-fluoro-β-D-ribo(arabino)furanosyl)
thymine ((75) and (76)), and 9-(β-D- arabinofuranosyl)gua-
nine (21; aG). Incubation of the enzyme (2 microM) with ara-
binosyl nucleosides (72), (74), or aG (21) (100 microM) at 25 °C 
for 20 min resulted in inhibition of transferase activity by 91, 
72, and 21%, respectively; thymine nucleosides did not inhibit 
the enzyme. The inhibited enzyme contained stoichiometric 
amounts of covalently bound 2-deoxy-2-fluoro-D-arabinose, 
and its activity could be restored upon treatment with ad-
enine, which simultaneously yielded adenine arabinoside (72). 
Proteolysis of the inhibited enzyme yielded data that suggest 
that the γ-carboxylate of Glu-98 is esterified during catalysis 
(Scheme 14). Finally, a recombinant enzyme, in which the 
Glu-98 residue is replaced by alanine, showed a decrease in 
activity by 3 orders of magnitude as compared to the wild-
type recombinant enzyme. 
Later on, P.A. Kaminski obtained recombinant L. helve-
ticus PDT and NDT and determined that the polypeptides 
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display 25.6% identity in the region involved in the binding 
of substrate to the Glu-98 residue of the enzyme’s active site 
[109]. Both enzymes catalyzed the transformation of 2-ami-
nopurine and 2,6-diaminopurine into the corresponding 
2-deoxy-β-D-ribonucleosides at a rate comparable to that 
of natural purine bases. 4-Aminoimidazole-5-carboxamide 
(AICA) and imidazole-5-carboxamide (ICA) turned out to be 
poor substrates, and their trans-2-deoxyribosylation required 
large quantities of enzyme and extended incubation times. It 
is worth noting that the specific activity of PDT was higher 
than that of NDT in all four studied transglycosylation reac-
tions (no experimental details were given).
The structure of the recombinant purine 2′-deoxyribosyl-
transferase of L. helveticus (PDT) was determined by X-ray 
crystallography [93], and the structure was found to be some-
what similar to that of NDT from L. leichmanii [105]. It was 
determined that, in the case of L. helveticus PDT, Glu-101 
serves as the nucleophile in the active site, which attacks the 
glycoside carbon atom of the nucleoside, while the C3′ oxygen 
atom of the furanose moiety forms a hydrogen bond with one 
of the oxygen atoms in the carboxogroup of Glu-101 (Scheme 
12). Glycosylated PDT, which is formed after treatment 
with adenine arabinoside (72), contains a 2-deoxyfluoro-α-
D-arabinofuranose residue covalently bound to one of the 
oxygen atoms of Glu-101. Comparison of the PDT-2’-deoxy-
adenosine and PDT-6-selenoinosine complex structures [105] 
allows to explain the specificity of the enzymes for 2′-deoxy-
nucleosides: namely that the C2’ and C3’ oxygen atoms of the 
ribonucleoside are involved in the formation of a hydrogen 
bond with Glu-101, making the formation of an intermedi-
ate structure with a covalently bound carbohydrate residue 
impossible (Scheme 12).
Recently, a very interesting study aimed at creating 
NDT with improved activity in regard to the synthesis of 
2′,3′-dideoxy purine nucleosides was published by Kamin-
ski and co-workers [110]. The authors constructed random 
mutant libraries of ndt genes from L. leichmanii (Ll) and L. 
fermentum (Lf) with a variable frequency of nucleotide sub-
stitutions (between 1 and 10 per sequence), developed a func-
tional screening method, and selected the mutants, which 
were suited for the synthesis of 2′,3′-dideoxynucleosides. Se-
quencing of the corresponding genes revealed a single muta-
tion (G3A transition), which caused a small aliphatic amino 
acid to be replaced by a residue with a hydroxyl group, Ala-
15 was substituted for Thr (L. fermentum) or Gly-9 for Ser 
(L. leichmanii), respectively. This single amino acid substi-
tution was sufficient to enhance the substrate activity to-
wards dideoxynucleosides. The authors concluded that the 
2,3-dideoxyribosyl transfer activity requires an additional 
hydroxyl group at the 9th (Ll) or 15th (Lf) position, so as to 
overcome the absence of such a group in the corresponding 
substrate. Both artificial enzymes also displayed significantly 
improved transferase activity in regard to 2′,3′-didehydro-
2′,3′-dideoxy-β-D-ribofuranosyl nucleosides. It was shown 
(without experimental details) that the Lf-NDT A15T 
enzyme catalyzed the synthesis of 2′,3′-didehydro-2′,3′-
dideoxyadenosine and 2′,3′-didehydro-2′,3′-dideoxyinosine 
using 2′,3′-didehydro-2′,3′-dideoxyuridine (d4U) as a donor 
of the pentofuranose moiety at the mM scale and with a good 
yield (up to 70%) [110]. 
Comparison of transglycosylation reactions catalyzed by 
a crude enzyme (NDT) preparation from L. helveticus [111] 
and E. coli purine nucleoside phosphorylase (PNP; Sigma) 
yielded rather unexpected results [112, 113]. On the whole, 
it was shown that NDT-catalyzed reactions proceeded with 
higher regioselectivity as compared to those catalyzed by 
PNP, and the difference strongly depended on the structure 
of the acceptor-base (for details, see [24]).
N-deoxyribosyltransferses are not restricted to Lactoba-
cilli and have also been isolated from the protozoan parasites 
Critinia lucilliae (see, e.g., [109]) and Trypanosoma brucei 
brucei [114, 115]. The enzyme from T. b. brucei was purified 
over 400-fold to >95% homogeneity from the bloodstream 
form of this parasite, and its properties have been inves-
tigated [79]; a recombinant enzyme of the same origin was 
also prepared [80]. As opposed to Lactobacilli enzymes, the 
enzyme from T. b. brucei was found to be N-ribohydrolase 
with a preference towards inosine, adenosine, and guano-
sine as substrates. The kcat/Km values for the recombinant 
enzyme and inosine, adenosine, and guanosine as substrates 
were (×106 M-1·s-1) 1.6, 1.4, and 0.7, respectively. Pyrimidine 
and 2’-deoxynucleosides were poor substrates with kcat/Km 
values approximately 103 M-1·s-1 and 102 M-1·s-1, respectively. 
3-Deazaadenosine, 7-deazaadenosine (Tubercidin), and for-
micin B were found to be inhibitors with Ki values of 1.8, 59, 
and 13 microM respectively. To the best of our knowledge, 
this enzyme has not been used for the synthesis of nucle-
osides yet. 
To sum up all of the above, we must note that chemo-en-
zymatic (biotechnological) strategies are currently displacing 
multi-stage chemical processes, and this allows key transfor-
mations to be achieved with high selectivity and regio- and 
stereospecificity. Considerable progress in the production of 
biologically important analogs of natural nucleosides has been 
achieved through the rational combination of chemical and 
biochemical transformations. Use of recombinant nucleoside 
phosphorylases and N-deoxyribosyl transferases as biocata-
lysts for the synthesis of natural nucleosides and their modi-
fied analogs is of considerable importance for the creation 
of modern technological processes. We must also note that 
the two enzymatic groups complement one another and allow 
finding out a straightforward way to the desired compound. 
The use of chemo-enzymatic methods undoubtedly allows 
improvement of the price-quality ratio during the production 
of many medical drugs. 
NEW TRENDS IN BIOTECHNOLOGY OF NUCLEOSIDES
A number of studies published over the last decade give new 
impulse for the development of nucleoside biotechnology. 
Much attention is given to the use of α-D-pentafuranose-1-
phosphates as substrates for the enzymatic synthesis of nucle-
osides. It must be noted that both the enzymatic and chemical 
syntheses of D-pentofuranose-1-phosphates have extensive 
histories (see [24]). However, only several recently published 
works are interesting from a practical point of view. There 
are two main lines of research in this field: (i) biochemical 
(microbiological, enzymatic) retro-synthesis of 2′-deoxyribo-
nucleotides and (ii) chemical synthesis of D-pentofuranose-
1-phosphates and their subsequent enzymatic condensation 
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The metabolic transformations of pentoses have been 
investigated thoroughly (for a review, see, e.g., [116]). Both 
in bacteria and eukaryotic cells nucleosides are regarded as 
carriers of carbohydrates, which serve as sources of carbon 
and energy. α-D-Ribofuranose-1-phosphate (47) is mainly 
produced from purine nucleosides via a process catalyzed 
by PNP. This phosphate is then involved in (i) glycolysis, (ii) 
metabolic activation of pyrimidine heterobases, which results 
in the formation of ribonucleosides (e.g. transformation of 
5-fluorouracil into 5-fluorouridine catalyzed by UP), and (iii) 
an enzymatic transformation into 5-phospho-D-ribofuran-
ose, catalyzed by phosphopentomutase (PPM). This process is 
usually in a state of enzymatic equilibrium, and the product 
of this reaction (5-phospho-D-ribofuranose ) is a precursor 
of 5-phospho-α-D-ribofuranosyl-1-pyrophosphate (PRPP). 
The latter acts as a donor of the 5-phospho-D-ribofuranose 
moiety for both de novo and “salvage” synthesis of nucle-
osides. Catabolic transformations of 2′-deoxynucleosides also 
proceed under the control of nucleoside phosphorylases and 
PPM, and the resulting 2-deoxy-D-ribofuranose-5-phosphate 
(78) is then irreversibly metabolized into D-glyceraldehyde-
3-phosphate ((79); Gla-3P) and acetaldehyde (80) by bacte-
rial or eukaryotic deoxyriboaldolases (Scheme 15).
The reversed retro-pathway for nucleoside synthesis be-
ginning with Gla-3P and acetaldehyde was studied by J. Raap 
and co-workers [117, 118]. The authors described a one-pot 
two-step enzymatic reaction involving glycosylation of thy-
mine or uracil (labeled by 13C and 15N atoms) using 2-deoxy-
α-D-ribofuranose-1-phosphate ((48); also 13C-labeled at the 
different carbon atoms) and commercially available thymi-
dine phosphorylase (TP). Synthesis of 1-phosphate (48) was 
performed using 2-deoxy-D-ribofuranose-5-phosphate (78) 
by stereospecific phosphate C5 → C1 translocation catalyzed 
by partially purified recombinant phosphopentomutase. The 
13C-labeled 5-phosphates were enzymatically prepared from 
chemically synthesized dihydroxyacetone monophosphate 
(81) in the presence of an excess of acetaldehyde using de-
oxyriboaldolase (DERA) and commercially available triose 
phosphate isomerase (TRI; from baker’s yeast). The (78) → 
(48) transformation and condensation with thymine or ura-
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cil were carried out in a one-pot system, and the respective 
2′-deoxyribonucleosides were then isolated in yields of 50-
60% (Scheme 16). It should be stressed that the great excess 
of acetaldehyde is necessary to prevent the cleavage of Gla-
3P and to direct the metabolic reaction in the reverse syn-
thetic direction. 
A similar approach was used by J. Ogawa et al. for the 
synthesis of 2′-deoxynucleosides from acetaldehyde and di-
hydroxyacetone monophosphate through the intermediate 
formation of 5-phosphate (78) [119, 120]. The authors se-
lected the Klebsiella pneumoniae B-4-4 strain for clones that 
could efficiently synthesize 5-phosphate (78), which was then 
transformed into 1-phosphate (48) in the presence of trans-
formed E. coli pTS17/BL21 cells, expressing E. coli PPM. The 
1-phosphate (without any isolation procedures) was then con-
densed with adenine in the presence of commercially availa-
ble PNP, which yielded a ~1:16 mixture of 2′-deoxyadenosine 
(1) and 2′-deoxyinosine (82). Formation of the latter as the 
major product is due to the presence of adenosinedeaminase 
(ADA) in the E. coli pTS17/BL21 cells. This enzyme deami-
nates the initially formed 2′-deoxyadenosine (1). Notably, the 
K. pneumoniae B-4-4 strain tolerated high concentrations of 
acetaldehyde, which directs the reversible DERA-catalyzed 
reaction in the direction of 5-phosphate synthesis (78).
Later on, Ogawa and co-workers combined the alcoholic 
fermentation system of baker’s yeast and the DERA-ex-
pressing E. coli cells for the synthesis of 5-phosphate (78) 
[121 – 124]. The procedure for the synthesis of 2′-deox-
yribonucleosides consisted of four steps: 1 – baker’s yeast 
synthesize fructose-1,6-diphosphate (FDP) via alcoholic 
fermentation; 2 – the DERA expressing E. coli 10B5/pTS8 
cells transform FDP into an equilibrated mixture of dihy-
droxyacetone monophosphate (81) and D-glyceraldehyde-
3-phosphate (79); enzymatic condensation of (79) and acetal-
dehyde (the high concentration of acetaldehyde is necessary 
in order to prevent the reversed reaction!) produces 5-phos-
phate; 3 – the latter is transformed into 1-phosphate (48) 
under catalysis of PPM-expressing E. coli BL21/pTS17 cells; 
and finally step 4, accomplished in one pot in the presence 
of a heterocyclic base and commercially available purine 
nucleoside phosphorylase or thymidine phosphorylase, since 
the activity of both enzymes within the used E. coli cells was 
insufficient. 
Synthesis of 2’-deoxyadenosine (1) was also accompanied 
by the formation of 2’-deoxyinosine (82). Xylene and poly-
oxyethylenelaurilamine were used in order to improve the 
permeability of the E. coli cells, which in turn improved the 
yield of 5-phosphate (78).
Notably, microbial synthesis [119 – 124] appears to be 
limited to the production of 2′-deoxy-β-D-ribonucleosides 
(isolation of individual products has not been published as of 
now). Also, satisfactory solubility of heterocyclic bases in the 
reaction mixture is an important prerequisite for successful 
nucleoside synthesis (for instance, low solubility of guanine 
makes synthesis of 2′-deoxyguanosine highly improbable). It 
is also important to bear in mind the off-pathway activities 
present in the employed cells, which can prevent efficient 
synthesis of the desired product. 
The second line of research, chemo-enzymatic synthe-
sis, involves chemical synthesis of α-D-pentofuranose-1-
phosphates, which are then used for enzymatic condensation 
with heterocyclic bases. This line of research presents more 
Scheme 16
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possibilities for variety and is promising for the synthesis 
of biologically important nucleosides and their analogs with 
modifications in the carbohydrate and base fragments. In-
deed, α-D-pentofuranose-1-phosphates are universal gly-
cosylation agents and can be used for the synthesis of both 
purine and pyrimidine nucleosides, as well as for reactions 
with any other type of heterocyclic base which can act as a 
substrate for nucleoside phophorylases. 
The effectiveness of this strategy was demonstrated in 
a very convincing manner almost simultaneously with the 
discovery of nucleoside phosphorylases and N-deoxyribosyl 
transferases. In this context, we must also note the pioneering 
studies on phosphorolysis and resynthesis of purine 2’-de-
oxyribosides involving mammalian nucleoside phosphory-
lases [40–49], purification of 2’-deoxy-α-D-ribofuranose-1-
phosphate (48) as crystalline cyclohexylammonium salt [24, 
53], and the synthesis of thymidine and a number of 5’-modi-
fied pyrimidine 2′-deoxyribonucleotides [57, 58]. Further 
studies also managed to create procedures for the chemical 
synthesis of α- and β-anomers of D-ribofuranose-1-phos-
phate and 2-deoxy-D-ribofuranose-1-phosphate (see [24]). 
A group of researchers from Mitsui Chemicals is also in-
vestigating the synthesis of nucleosides via condensation of 
α-D-pentofuranose-1-phosphates with heterobases using nu-
cleoside phosphorylases [125–127]. First of all, they have de-
veloped “crystallization-induced asymmetric transformation” 
for the stereoselective synthesis of 2-deoxy-α-D-ribofuranose-
1-phosphate (48) and its β-D-anomer [125, 126]. Both anomers 
have been isolated as pure stable bis(cyclohexylammonium) 
salts. It was also clearly shown that the former is a substrate for 
PNP, while the β-D-anomer did not show any substrate activ-
Scheme 19
ity, as was expected. 2-Deoxy-α-D-ribofuranose-1-phosphate 
(48) was used for the synthesis of 2′-deoxy-2-chloroadenosine 
(Cladribine) via one-step condensation with 2-chloroadenine 
or via a two-step process involving the intermediary formation 
of 9-(2-deoxy-β-D-ribofuranosyl)-2,6-dichloroadenine [128]. 
This method was then successfully extended to the synthe-
sis of 2,3-dideoxy-3-fluoro-5-О-[(4-phenyl)benzoyl]-D-ribo-
furanose-1-phosphate (in the form of a ≈ 87 : 13 mixture of 
the  α- and β-anomers (85) and (84)) from methyl-2-deoxy-
D-ribofuranoside (83), and the α-anomer from this mixture 
was then used as the main PNP substrate (after the removal 
of the 5-О-blocking group) for the synthesis of 2′,3′-dideoxy-
3′-fluoroguanosine (86) via enzymatic glycosylation of guanine 
(Scheme 19) [127, 129].
This study is of vast importance for further development 
of this field of research, since it gives a clear answer to the 
following question: if the potential carbohydrate-modified 
nucleoside donor shows extremely low substrate activity to-
wards the relevant nucleoside phosphorylase (like FLT (17) 
towards TP and UP) does this mean that the corresponding 
α-D-pentofuranose-1-phosphate (such as  2,3-dideoxy-3-
fluoro-α-D-ribofuranose-1-phosphate) will also be lacking 
in substrate activity towards the same nucleoside phospho-
rylase? It is known that a number of pyrimidine nucleosides, 
which are easily synthesized via chemical methods, cannot 
act as substrates for TP and/or UP and thus cannot be used 
as pentose donors. Chemical synthesis of the appropriate α-D-
pentofuranose-1-phosphates and assaying of their substrate 
qualities is of vast interest. The study by H. Komatsu et al. 
[127] is very revealing and demonstrates the need for further 
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Recently, J.M. Montserrat et al. described a chemo-enzy-
matic approach to the nucleoside synthesis involving D-ribose, 
2’-deoxy-D-ribose, and D-arabinose [130]. Pentoses were 
transformed into 5-phosphates (in the form of sodium salts) 
using chemical methods which sometimes utilized lypases for 
the introduction or removal of protective groups. The com-
bined effect of PPM, which catalyzes the transformation of 
5-phosphates into 1-phosphates, and condensation of the latter 
with heterobases in the presence of PNP or TP, leads to the 
formation of the appropriate nucleosides (Scheme 20).
The work of Montserrat et al. is very interesting as an exam-
ple of rational chemo-enzymatic synthesis of D-pentofuranose-
5-phosphates (compare the above work with [118, 119, 121–
123]). We must of course note the universal approach to the 
synthesis of D-pentafuranose-5-phosphates, since the use of 
lypases for the regioselective introduction and removal of pro-
tective groups seems not to be limited to the studied pentoses.
The synthesis of 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) 
purines described in the study by K. Yamada et al. is also of 
considerable interest [131, 132]. In this case, there are no easy 
and simple methods for the synthesis of the potential carbo-
hydrate fragment donor, which is why the chemical synthe-
sis of 2-deoxy-2-fluoro-α-D-arabinofuranose-1-phosphate 
(96) and its use as a universal glycosylation agent seems to 
be a reasonable alternative to the chemical glycosylation of 
heterobases (Scheme 21). Commercially available 1-О-acetyl-
Scheme 20
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3,5-di-О-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranose 
was used as the initial compound (93), which was then 
transformed into a bromide (94) and then into a ≈3 : 1 mix-
ture of α- and β-phosphates (96) and (95). This mixture was 
used for the synthesis of N9-purine 2-deoxy-2-fluoro-β-D-
arabinofuranosyl nucleosides without isolation of the individ-
ual α-anomer (96), and the results were satisfactory. We must 
note that in some cases chemical glycosylation results in the 
formation of an anomeric mixture (purines and pyrimidines) 
and regioisomers (purines) [11, 12].
An analysis of the above-mentioned results leads to the 
conclusion that the laborious and low-yielding preparation of 
α-D-pentofuranosylphosphates is a serious bottleneck of this 
approach. However, despite this downside, it is an approach 
to the synthesis of biologically valuable nuclosides that is un-
doubtedly worthy of further investigation and is a valuable 
addition to the chemo-enzymatic methods reviewed above. 
We recently proposed a novel nucleoside synthesis strat-
egy which consists of the sequential transformation of pen-
toses into nucleosides in the presence of heterobases. The 
process is catalyzed by recombinant E. coli enzymes, namely 
ribokinase (RK) (D-pentose → D-pentose-5-phosphate (D-PF-
5P)), phosphopentomutase (D-PF-5P → α-D-pentofuranose-
1-phosphate (D-PF-1P)), and nucleoside phosphorylases (NP) 
(D-PF-1P + heterobase → nucleoside) (Scheme 22) [133].
Production of recombinant RK, as well as that of uridine-, 
thymidine-  and purine-nucleoside phosphorylases, was de-
scribed in our previous work [134]. We observed that under 
optimal conditions RK can catalyze the phosphorylation of 
the primary hydroxyl group not only of D-ribose and 2-de-
oxy-D-ribose, but also of D-arabinose and D-xylose. These 
data suggest that RK may be used as a biocatalyst for the 
first step of the cascade transformation of pentoses into nu-
cleosides. Stereospecific C5 →C1-translocation of phosphate 
by PPM is a reliable bridge within the proposed by us strat-
egy of transformation of pentose into nucleoside, and this was 
the reason to produce recombinant PPM. The preliminary 
results of the transformation of D-ribose or 2-deoxy-D-ribose 
into pyrimidine and purine nucleosides using purified recom-
binant E. coli RK, PPM, and nucleoside phosphorylases were 
recently published (Scheme 23) [135].
An analysis of the optimal reaction conditions for RK [133], 
PPM, and NP [134] showed considerable differences. Bear-
ing this in mind, compromise conditions were chosen for a 
one-pot cascade transformation of pentoses into nucleosides. 
These conditions allow for the satisfactory activity of all the 
used enzymes and are as follows: overall volume of the reac-
tion mix 2 ml; contents of the buffering solution: 2 mM ATP, 
50 mM KCl, 3 mM MnCl2, 20 mM Tris-HCl (pH 7.5), 2 mM 
pentose, 2 mM heterobase; reaction temperature 20 °C; and 
enzymes (in the appropriate units): RK 7.65; PPM 3.9; TP 4.5; 
UP 5.4; PNP 4.68. The results of the D-ribose and 2-deoxy-D-
ribose transformation into pyrimidine and purine nucleosides 
are presented in Scheme 23 and Table 1.
Notably, inosine is formed at a faster rate compared to 
2′-deoxyinsoine, and the maximum yield is achieved after 30 
minutes. Also, the synthesis of purine deoxyribonucleotides 
was much more effective under transglycosilation conditions 
as compared to ribonucleside synthesis [82–84]. Obviously, 
the studied conditions for the cascade transformation of pen-
Scheme 22
Table 1. Progress of nucleoside syntheses in cascade one-pot 
enzymatic reactions at 20°C  [content of the corresponding 
nucleoside (%) in the reaction mixture vs time of reaction].
Time of 
Reaction, 
h
Inosine
(Ino)
2’-Deoxy-
inosine 
(dI)
Thymidine 
(Thd)/2’-
Deoxyuridine 
(dU)[a]
1-(β-D-
Ribofuranosyl)thy-
mine (Rib-Thy)/
Uridine(Urd)[a]
0.5 45.9 18.8 14.5/0.9 4.7/27.6
1 46.1 27.3 17.6/1.1 8.5/26.6
24 38.4 38.3 - -
44 - - 34.7/33.2 19.9/17.5
96 29.4 34.4 - -
[a] Thymidine (TP) and uridine (UP) phosphorylases were 
employed for the synthesis of thymine and uracil nucleosides, 
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toses into nucleosides require thorough optimization for higher 
yields of the desired products. Showcase synthesis of Cladrib-
ine (31) shows that a 1.5 : 1 mixture of 2-deoxy-D-ribose and 
2-chloroadenine (100) (mole/mole) substrates results in a prod-
uct yield in excess of 90% (Scheme 24) [136].
As was noted earlier, chemical synthesis of α-D-
pentofurnanose-1-phosphates is relatively complex, which 
means that these compounds will probably not gain wide-
spread in for the production of preparative amounts of nu-
cleosides. Preliminary results of the cascade transformation 
of pentoses into nucleosides using three enzymes indicate 
that this strategy is worth investigating further in terms of 
its limitations and possibilities for use.
A survey of the chemical methods for the production of 
pento(hexo)-furanose-1-phosphates [125–132, 137–147] and 
the methods of anomeric carbon atom activation (see [139] 
Scheme 23
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for a review) shows that most of these methods are laborious 
and low-yielding of the desired phosphates. As can be expect-
ed, most of the procedures yield mixtures of anomers, and it 
seems that only the “crystallization-induced asymmetrical 
transformation” preferably yields the desired 2-deoxy-α-D-
pentofuranose-1-phosphates [85].
Because of its relative simplicity, the method proposed 
by D.L. MacDonald [140–144] seems to be the most effec-
tive, which is why we chose to use it for the synthesis of 
α-D-pentofuranose-1-phosphates. The method proposed by 
MacDonald is effective for the synthesis of hexopyranose-
1-phosphates and was also used for the synthesis of α-L-
arabinofuranose-1-phosphate in a study by G.O. Aspinall et 
al.: incubation of a peracetyl-derivative of L-arabinofuranose 
(mixture of α-, β-anomers) in anhydrous phosphoric acid and 
anhydrous THF at 50°C for 2 h yielded a mixture of L-arab-
inofuranose-1-phosphate (mostly α-L-anomer) and L-arabi-
nopyranose-1-phosphate (both in the form of cyclohexylam-
monium salts) in an overall yield of 19% [147]. However, there 
were no conclusive physico-chemical data in support of the 
indicated structures.
Bearing in mind that a large number of purine and py-
rimidine β-D-arabinofuranosides exhibit strong antiviral 
Scheme 25
and antitumor activity (see above and also [18, 19, 148–150]), 
we chose the MacDonald approach for the synthesis of D-
arabinofuranose-1-phosphate and used it for the synthesis of 
purine nucleosides.
A freshly prepared D-arabinose tetraacetate was a mix-
ture of α-,β-anomers of furanose (101) and pyranose (102) 
forms (compare with [151]); treatment of this mixture ac-
cording to the MacDonald method yielded an amorphous 
mixture of α-D-arabinofuranose-1-phosphate (50) and β-D-
arabinopyranose-1-phosphate (103) (overall yield ≈ 50%; iso-
mer ratio from 1.5 : 8 to 1 : 2, as assayed by 1H-NMR). This 
mixture was tested in reactions with 2-fluoroadenine (104) 
and 2-amino-6-methoxypurine (105), catalyzed by recombi-
nant E. coli PNP.
We observed that pyranose 1-phosphate (102) does 
not inhibit the synthesis of 9-(β-D-arabinofuranosyl)-2-
fluoroadenine ((32); Fludarabine) under optimal conditions 
(water solution, pH 7.0, 55 °C; 1 hour). This procedure had a 
yield of 77% (Scheme 25) [152]. Unexpectedly, the rate of Flu-
darabine formation was similar to the rate of 2-fluoroadenos-
ine synthesis from α-D-ribofurnaose-1-phosphate (Sigma) 
and 2-fluoroadenine (104) in the presence of recombinant 
PNP extracted from E. coli.56 | ACTA NATURAE |  VOL. 2  № 2 (5)  2010
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The high rate of Fludarabine formation was unexpected 
(compare with [130]). In chemical terms, the condensation 
of α-D-pentofuranose-1-phosphates with heterobases is 
the result of a nucleophilic attack of the heterobase nitro-
gen atom on the electrophilic anomeric carbon atom of the 
1-phosphate. In order to asses the electrophilic properties of 
the С1-atom, we used an ab initio method for the geometry 
optimization of a number of related phosphate structures, 
namely α-D-ribofuranose-1-phosphates ((47); Ribf-α1P), 
α-D-2-deoxyribofuranose ((48); dRibf-α1P); and ((50) Araf-
α1P) (Table 2).
It follows from the data in Table 2 that the positive partial 
charges of the С1-atoms of 2-deoxyribo- and arabino-phos-
phates are similar in value and are stronger than the charges 
of the ribo-isomer. The latter has the C-2 hydroxyl and phos-
phate group in cis-conformation and is more stable than the 
arabino-phosphate. The spatial structures of the ribo- and 
2-deoxyribo-phosphates are more favorable for nucleophilic 
attack, and the С2-hydroxyl of the arabino-isomer does not 
create significant steric barriers for the approach of the base 
towards the С1-atom [152].
Differences in the partial positive charge of the С1-atoms 
of ribo- and 2-deoxyribo-phosphates are confirmed by the 
fact that trans-deoxyribosylation is more effective than 
trans-ribosylation of deazapurines [24, 82] and benzimida-
zoles [24, 83, 84]. A similar substrate activity of Ribf-α1P and 
Araf-α1P in a reaction with 2-fluoroadenine can seemingly 
be explained by two interacting factors: the high partial posi-
tive charge of the С1-atom of Araf-α1P, on the one hand, and 
the negative steric effect of the С2-hydroxyl, on the other 
(compare this with data from [130]).
It shoud be noted that calculations indicate that both con-
formers of β-D-arabinopyranose-1-phosphate, namely 4C1 
and 4C1, have higher thermodynamic stability as compared to 
Araf-α1P. These differences seem to account for the prefer-
ential formation of pyranose phosphate during the MacDon-
ald reaction. 
Unlike 2-fluoroadenine, a reaction between 2-amino-6-
methoxypurine (105) and Araf-α1P (in a mixture with Arap-
β1P) in the presence of recombinant E. coli PNP under condi-
tions specified earlier reached equilibrium at an equimolar 
ratio between the initial heterobase and reaction product, 
2-amino-9-(β-D-arabinofuranosyl)-6-methoxypurine ((34); 
Nelarabine), which could then be isolated in a yield of 44%. 
This result is in accordance with an earlier Nelarabine 
synthesis in a yield of 53% and involved the transarabino-
sylation of 2-amino-6-methoxypurine (105), using 1-(β-D-
arabinofuranosyl)uracil (49) as a carbohydrate group donor 
and E. coli UP and PNP as biocatalysts [153].
We have observed earlier that trans-2-deoxyribosylation 
of N2-acetylguanine with thymidine or 2′-deoxyguanosine as 
a carbohydrate group donor and TP/PNP or PNP as a biocat-
alyst initially leads to the formation of N2-acetyl-7-(2-deoxy-
β-D-ribofuranosyl)guanine, which eventually rearranges into 
the more thermodynamically stable N2-acetyl-9-(2-deoxy-β-
D-ribofuranosyl)guanine [76]. On the contrary, the Fludara-
bine and Nelarabine syntheses did not involve similar reac-
tion stages [152]. This result allows us to hypothesize that the 
electron structure of the heterocyclic base determines the 
heterobase’s mode of binding in the PNP active site, thus de-
termining the regioselectivity of the enzymatic reaction. 
CONCLUSION
An analysis of the results of the chemoenzymatic synthe-
ses of nucleosides clearly indicates that this methodology is 
highly effective and very promising for the development of 
biotechnological processes for the production of biologically 
important compounds. Glycosylation of heterocyclic bases is 
catalyzed by two types of enzymes: nucleoside phosphory-
lases and N-deoxyribosyl transferases. These enzymes exhibit 
varying substrate specificities, which is why they mutually 
complement in terms of their use as biocatalysts. 
Overall, all the above-mentioned results demonstrate the 
clear advantages of enzymatic methods for nucleoside syn-
thesis as opposed to chemical methods. First of all, enzymatic 
methods fully conform to the principles of “green chemistry,” 
since routinely they do not use aggressive reagents (apart 
from acetic aldehyde) or organic solvents. Secondly, the high 
effectiveness of enzymatic transformations and their stereo- 
(only β-D-nucleosides!) and regioselectivity (apart from some 
specific cases) simplify the production of the desired com-
pounds and increase the product’s quality. All of these fac-
tors lower the costs of production of biologically important 
compounds, making these compounds more available for re-
searchers, and making drugs more available for widespread 
use.  
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Table 2. Results of the ab initio geometry optimization proce-
dure (HyperChem, 8.1; in vacuo, 6-31G* level) for the spatial 
structures of α(β)-D-pentofuranose(pyranose)-1-phosphates (in 
mono sodium salt form). 
Compound
Positive partial 
charge at the 
C1 carbon 
atom
Total 
(binding) 
energy 
kcal/mol
Conformation 
of the pento-
furanose(pyranose) 
ring
(47); Ribf-α1P 0.425 -808 850.3 C1-exo
(48); dRibf-α1P 0.454 -762 140.7 C3-endo
(50); Araf-α1P 0.464 -808 841.6 O4-exo
0.410 -808 868.5 4C1 (more stable)
(103) Arap- 
β1P 0.451 -808 856.8 4C1 (less stable)REVIEWS
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